ONO-2370 Phase 1 Study: Bioequivalence and levodopa co-administration Study ONO-2370

Trial Profile

ONO-2370 Phase 1 Study: Bioequivalence and levodopa co-administration Study ONO-2370

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Opicapone (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 19 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top